Caplin Point Q1FY27: PAT +18.8% YoY to ₹179 Cr, EBITDA margin expands, tax caps NPM

Caplin Point's consolidated Q1 FY27 revenue from operations came in at ₹610.4 Cr, up 19.6% YoY (₹510.2 Cr) and 1.7% QoQ; total revenue (including other income) was ₹643.9 Cr, +20.7% YoY. Consolidated PAT (net profit for the period, before minority interest) was ₹179.1 Cr, up 18.8% YoY and 3.6% QoQ, with basic EPS of ₹23.27 versus ₹20.10 a year ago. Neither the current nor the year-ago quarter carries any exceptional item, so this is a clean, comparable growth number. Management issued no formal quantitative guidance ahead of this print, so there is no company target to grade against; the closest available yardstick is broad analyst consensus (not quarter-specific) pegging FY27 PAT growth at 15-20% — the 18.8% YoY print sits within that band.

The operating story was actually stronger than the PAT growth alone suggests: EBITDA rose 23.0% YoY to ₹247.0 Cr with the EBITDA margin expanding to 38.4% from 37.7%, and PBT/EBIT margin rose to 35.0% from 34.6%. But gross margin slipped to 59.8% from 61.7% YoY as purchased/traded goods took a larger share of the cost mix, and the effective tax rate jumped to 20.5% (₹46.1 Cr tax on ₹225.2 Cr PBT) from 18.3% a year ago, compounded by a 32.8% YoY rise in depreciation as new capacity comes online. Net effect: consolidated PAT margin actually compressed to 27.8% from 28.3% YoY even as operating profitability improved — the quarter's real story is healthy operating leverage being partly offset below the line by tax and D&A, not a demand or pricing issue.

The stock went into the print at ₹2,590.85, down 2.5% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.

US revenue was the standout at ₹137 Cr (per the press release), +26% YoY, now roughly 22% of the geographic mix versus 78% for Emerging Markets; by segment, Rest-of-World PBT grew to ₹158.4 Cr (Q1FY26: ₹151.5 Cr) while the USA segment's PBT nearly tripled YoY to ₹33.3 Cr (from ₹9.9 Cr) — the regulated-market business is scaling faster than its still-smaller revenue base, backed by Caplin Steriles' 60 approved ANDAs (40+ more filing/in development) and CSU's own-label US business (33 launches to date, ~90% market-share retention on launched products). Alongside results, the board recommended a ₹4/share (200%) final dividend on top of the ₹4 interim already paid in June, taking total FY26 dividend to ₹8/share, and approved Dr. Sridhar Ganesan's MD reappointment (two more years from Aug 25, 2026) plus D. Muralidharan's elevation to Whole-Time Director while he retains the CFO role. Chairman C.C. Paarthipan's press-release commentary framed the quarter as delivering "healthy growth across both Emerging Markets and the US" with "disciplined execution" — the revenue and EBITDA numbers support that framing, though management's commentary does not address the tax-rate increase that capped net profit growth.